Chemoradiotherapy With Generic Cisplatin Formulations for Head and Neck Cancers

The use of generic drugs has been increasing. However, studies of the safety of generic cisplatin (CDDP) for the treatment of head and neck cancer (HNC) have not been reported. This study investigated the treatment completion rates and incidence of CDDP-related adverse events in patients with advanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimada, Rie, Tsukahara, Kiyoaki, Takase, Soichiro, Okamoto, Isaku, Sato, Hiroki, Katsube, Yasuaki, Maruyama, Ryo, Shimizu, Akira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802811/
https://www.ncbi.nlm.nih.gov/pubmed/29434483
http://dx.doi.org/10.1177/1179670717749231
_version_ 1783298592972210176
author Shimada, Rie
Tsukahara, Kiyoaki
Takase, Soichiro
Okamoto, Isaku
Sato, Hiroki
Katsube, Yasuaki
Maruyama, Ryo
Shimizu, Akira
author_facet Shimada, Rie
Tsukahara, Kiyoaki
Takase, Soichiro
Okamoto, Isaku
Sato, Hiroki
Katsube, Yasuaki
Maruyama, Ryo
Shimizu, Akira
author_sort Shimada, Rie
collection PubMed
description The use of generic drugs has been increasing. However, studies of the safety of generic cisplatin (CDDP) for the treatment of head and neck cancer (HNC) have not been reported. This study investigated the treatment completion rates and incidence of CDDP-related adverse events in patients with advanced HNC treated with concurrent chemoradiotherapy (CRT) using generic CDDP. This study included 72 patients who received concurrent CRT using generic CDDP. The number of courses of CDDP was 3 in 45 patients, 2 in 19 patients, and 1 in 8 patients. During 154 courses of 80 mg/m(2) generic CDDP, grade 3/4 leukopenia in 21 (14%), neutropenia in 18 (12%), and hypochromia in 8 (5%) cases were reported. Grade 2 elevated serum creatinine occurred in 4 cases (3%), but no grade 3/4 elevated serum creatinine was reported. These results suggest that CRT using generic CDDP is well tolerated in patients with HNC.
format Online
Article
Text
id pubmed-5802811
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-58028112018-02-12 Chemoradiotherapy With Generic Cisplatin Formulations for Head and Neck Cancers Shimada, Rie Tsukahara, Kiyoaki Takase, Soichiro Okamoto, Isaku Sato, Hiroki Katsube, Yasuaki Maruyama, Ryo Shimizu, Akira Jpn Clin Med Original Research The use of generic drugs has been increasing. However, studies of the safety of generic cisplatin (CDDP) for the treatment of head and neck cancer (HNC) have not been reported. This study investigated the treatment completion rates and incidence of CDDP-related adverse events in patients with advanced HNC treated with concurrent chemoradiotherapy (CRT) using generic CDDP. This study included 72 patients who received concurrent CRT using generic CDDP. The number of courses of CDDP was 3 in 45 patients, 2 in 19 patients, and 1 in 8 patients. During 154 courses of 80 mg/m(2) generic CDDP, grade 3/4 leukopenia in 21 (14%), neutropenia in 18 (12%), and hypochromia in 8 (5%) cases were reported. Grade 2 elevated serum creatinine occurred in 4 cases (3%), but no grade 3/4 elevated serum creatinine was reported. These results suggest that CRT using generic CDDP is well tolerated in patients with HNC. SAGE Publications 2018-01-29 /pmc/articles/PMC5802811/ /pubmed/29434483 http://dx.doi.org/10.1177/1179670717749231 Text en © The Author(s) 2018 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Shimada, Rie
Tsukahara, Kiyoaki
Takase, Soichiro
Okamoto, Isaku
Sato, Hiroki
Katsube, Yasuaki
Maruyama, Ryo
Shimizu, Akira
Chemoradiotherapy With Generic Cisplatin Formulations for Head and Neck Cancers
title Chemoradiotherapy With Generic Cisplatin Formulations for Head and Neck Cancers
title_full Chemoradiotherapy With Generic Cisplatin Formulations for Head and Neck Cancers
title_fullStr Chemoradiotherapy With Generic Cisplatin Formulations for Head and Neck Cancers
title_full_unstemmed Chemoradiotherapy With Generic Cisplatin Formulations for Head and Neck Cancers
title_short Chemoradiotherapy With Generic Cisplatin Formulations for Head and Neck Cancers
title_sort chemoradiotherapy with generic cisplatin formulations for head and neck cancers
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802811/
https://www.ncbi.nlm.nih.gov/pubmed/29434483
http://dx.doi.org/10.1177/1179670717749231
work_keys_str_mv AT shimadarie chemoradiotherapywithgenericcisplatinformulationsforheadandneckcancers
AT tsukaharakiyoaki chemoradiotherapywithgenericcisplatinformulationsforheadandneckcancers
AT takasesoichiro chemoradiotherapywithgenericcisplatinformulationsforheadandneckcancers
AT okamotoisaku chemoradiotherapywithgenericcisplatinformulationsforheadandneckcancers
AT satohiroki chemoradiotherapywithgenericcisplatinformulationsforheadandneckcancers
AT katsubeyasuaki chemoradiotherapywithgenericcisplatinformulationsforheadandneckcancers
AT maruyamaryo chemoradiotherapywithgenericcisplatinformulationsforheadandneckcancers
AT shimizuakira chemoradiotherapywithgenericcisplatinformulationsforheadandneckcancers

Ejemplares similares